Health & WellnessTech
People of Color
Vironix Health Inc.
AI-powered software for early detection of heart and lung failure
Austin,
TX
Investment type:
Equity
(Priced Round)
Target raise:
$50,006
- $1,069,989
Minimum investment:
$250
$250
End date:
Nov 24, 2022
Nov 24, 2022
ended
Share
Highlights
- ?? $150 million Potential ARR from Current LOIs (not guaranteed)
- ?? 2021 Mass Challenge Accelerator Alum & ? Certified Minority Controlled Enterprise
- ?? World-class R&D collaboration with Oxford University
- ?? APIs raise wellness, scale globally, & grow revenue for caregivers
Our Story
Vironix Ai-remote monitoring helps patients and caregivers to catch and intervene early on damaging flare-ups of heart and lung illness (Heart Failure, COPD, Asthma, Covid-19). Our major advantage is that our APIs are disease-specific, clinically validated, gamified, and integrated in existing patient applications. Thus, we show much higher adoption than alternatives, scale globally at low cost, and raise wellness. Vironix generates up to $300 per patient per month in insurance reimbursement.
Our Ambition
1) The global leader on preventative care technology with the highest proven track record for saving lives. 2) $250M annual recurring revenue 3) 50,000 physician customers and 10M API subscribers. 4) The most respected global organization for clinical and scientific research in chronic and acute lung & heart illness.